Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.55 |
| ▸ | CA5A | P35218 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8520095 | 0.85 | SMN1; SMN2 (0.65) | CA12CA1CA2CA4CA5A | |
| SCHEMBL909605 | 0.83 | CYP1A2 (0.68) | CA12CA1CA2CA4CA5A | |
| SCHEMBL1715548 | 0.83 | CYP1A2 (0.73) | CA12CA1CA2CA4CA5A | |
| SCHEMBL185651 | 0.81 | CYP1A2 (0.71) | CA12CA1CA2CA4CA5A | |
| SCHEMBL7706443 | 0.78 | SMN1; SMN2 (0.63) | CA12CA1CA2CA4CA5A | |
| SCHEMBL14916510 | 0.76 | CYP1A2 (0.54) | CYP1A2SMN1; SMN2GAAALDH1A1MAPT | |
| SCHEMBL222683 | 0.75 | GPR119 (0.49) | CA12CA1CA2CA4CA5A | |
| SCHEMBL19707336 | 0.75 | CYP1A2 (0.47) | CA12CA1CA2CA4CA5A | |
| SCHEMBL7883371 | 0.73 | OPRL1 (0.52) | CA12CA1CA2CA4CA5A | |
| SCHEMBL12456467 | 0.73 | CYP1A2 (0.50) | CA12CA1CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-30 | — | — | US | disclosed |
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | disclosed |
| CN-116003328-A | Diaryl hydantoin compounds | 加利福尼亚大学董事会 | 2023-04-25 | — | — | CN | disclosed |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| CN-110003114-B | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2023-01-17 | — | — | CN | disclosed |
| EP-3970721-A1 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| US-20200079741-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-11 | — | — | US | disclosed |
| US-20180086718-A1 | Diarylhydantoin Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | disclosed |
| EP-2561871-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120295944-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | US | disclosed |
| US-8183274-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2444085-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-1893196-B1 | DIARYLHYDANTOIN COMPOUND | UNIV CALIFORNIA (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-08 | — | — | US | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | CA12 342/4885CA1 230/4885CA2 555/4885 |
| US-20120295944-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | CDK4, CCNH, VHL | CA12 2918/4885CA1 4168/4885CA2 2967/4885 |
| US-20180086718-A1 | Diarylhydantoin Compounds | BPHL, AR, SHBG | CA12 342/4885CA1 230/4885CA2 555/4885 |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | AR, BRDT, GNRHR | CA12 793/4885CA1 1181/4885CA2 1069/4885 |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | CDK4, CCNH, VHL | CA12 2918/4885CA1 4168/4885CA2 2967/4885 |
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | CA12 342/4885CA1 230/4885CA2 555/4885 |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | CA12 342/4885CA1 230/4885CA2 555/4885 |
| US-20200079741-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | CA12 342/4885CA1 230/4885CA2 555/4885 |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | FAP, LEF1, LPXN | CA12 392/4885CA1 502/4885CA2 1235/4885 |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | CA12 342/4885CA1 230/4885CA2 555/4885 |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | CA12 342/4885CA1 230/4885CA2 555/4885 |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | CA12 342/4885CA1 230/4885CA2 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.